STAT1h
Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...
Merck Expands Oncology Pipeline By Securing License For LaNova Medicines' LM-299
Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has ...
Merck signs up to $3.3 billion cancer drug deal with China-based LaNova
(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on ...
Hosted on MSN5h
Growth brings higher profits at Germany's Merck
Driven by growth across the board, including in its semiconductor business, German science and technology company Merck ...